Aussies are missing out on hundreds of thousands of dollars in superannuation returns, according to one of the nation’s largest super funds.

Percheron Therapeutics' board of directors has written a letter to shareholders following failure of its phase 2b trial.

Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a ...

Morningstar’s analyst picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.

With pending news flow of significance coming in 2025, these ASX-listed gas companies could be worth putting on your radar.

Gold prices rose ~1.5% on Thursday and Friday, following on from a ~26% annual gain, the metal's ninth best in 50 years.

Elevate Uranium, Bannerman Energy and Lotus Resources have made some of the biggest gains amongst the uranium companies ...

The ASX's strong performance last year means investors need to dig deeper for value – and the small to mid cap sector is the ...

The co-developer of a US-approved drug, Professor Andrew Wilks has formed Synthesis Bioventures to sniff out more winners.